Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, the researchers reviewed psychiatric drugs approved between 2002 and 2022 to analyze trends in drug repurposing, finding an increased application of repurposing methods, especially through fixed-dose combinations, and highlighting technologies like SmartCube® to predict efficacy from animal models.

This study found that in rodent models, the ability of D1 dopamine receptor activation to impair sensory gating is facilitated by 5α-reductase type 1, which produces allopregnanolone.

This study found that albumin-bound paclitaxel combined with nedaplatin shows promise as neoadjuvant therapy for esophageal squamous cell carcinoma, achieving a high complete response rate with manageable side effects.

This study suggests that KRTAP2-3 may serve as a novel biomarker to identify cells in the polyaneuploid cancer cell state, which is linked to therapy resistance and poor prognosis in prostate cancer.

This study identified neprilysin as a potential target of the pharmacological agent arteannuin, which may guide future research into its clinical applications, although experimental verification is needed.

This review covers drug repurposing patent applications from April to June 2021, detailing potential new therapeutic uses for existing medications, but reports no new clinical results; the authors highlight novel treatment possibilities and suggest further research.

In this study, researchers validated a computational workflow for repurposing non-antibacterial drugs as antibacterial agents and highlighted daprodustat, combined with an efflux pump inhibitor, as a promising strategy against bacterial pathogens.

This study observed that 100% of cancer patients at Dr. Moewardi Surakarta Hospital receiving carboplatin-paclitaxel chemotherapy experienced grade 2 alopecia as an adverse drug reaction.

This study used computational methods to identify pranlukast and mirabegron as promising candidates for repurposing against diabetes due to their good binding interactions with the DPP-IV target.

This review article discusses current trends and future perspectives in drug repurposing, highlighting its potential to discover novel treatments for unmet medical needs by identifying new uses for existing drugs, which benefits from faster development timelines and established safety profiles.

Repaglinide-loaded liponiosomal hybrids improve blood sugar control and insulin release better than regular Repaglinide.

This article hypothesizes that apremilast, a phosphodiesterase 4 inhibitor, could be a targeted treatment for alopecia areata due to its ability to suppress interferon-gamma production, but reports no new clinical results.

This article discusses drug repurposing as a strategy to find new uses for existing medications, highlighting its potential benefits like faster development and lower costs, while also addressing challenges such as drug specificity, ethical concerns, and regulatory issues.

This study described a case where both alopecia universalis and Crohn's ileitis in a 23-year-old man showed remarkable improvement with the JAK1 inhibitor upadacitinib, highlighting its potential as a treatment for patients with concurrent conditions.

In this case report, a female patient with both psoriasis and lichen planus initially responded to acitretin and topical mometasone but experienced a relapse after stopping the treatment. The authors reported marked improvement within 3 months after switching to upadacitinib, aiming to guide clinical decision-making.

This review discusses recent advances in monophosphate prodrug strategies for HCV drug discovery, aiming to enhance oral absorption and stability, and reports no new clinical results.

In this case report, researchers observed that a 35-year-old male with alopecia universalis achieved full regrowth of scalp, eyebrow, and facial hair with oral upadacitinib treatment after previous therapies failed to provide lasting relief.

This review examines the patent literature on AKR1C3 inhibitors and suggests that although numerous potent inhibitors exist, further preclinical optimization is necessary before assessing their therapeutic potential in human diseases.

This study found that combining data from different databases provided a more comprehensive estimate of serious adverse drug reactions in a French university hospital, highlighting the limitations of current ADR reporting methods.

This study identified common and previously unlisted adverse events associated with four anti-CGRP monoclonal antibodies for migraine prevention, highlighting a varied safety profile post-marketing.

This article highlights the importance of recognizing, preventing, and reporting adverse drug reactions to the FDA's MedWatch program, but does not present new research findings.

In this case study, upadacitinib treatment for a patient with coexisting ulcerative colitis and alopecia universalis resulted in significant hair regrowth and maintained UC remission, suggesting potential for treating similar dual-diagnosed cases.

This case report from the University of Alabama, Birmingham describes a rare paradoxical reaction of increased agitation and hyperactivity in a patient with schizoaffective disorder treated with divalproex sodium.

This study found that 4-aminopyridine, a potassium channel blocker, greatly improves skin wound healing by accelerating wound closure, enhancing tissue regeneration, and promoting hair follicle neogenesis.

In this cross-sectional study at a hospital in Nandyala, researchers identified nine drugs with potential new uses, noting that Aspirin and Dapagliflozin were most frequently repurposed, and observed changes in indications, dosage, and frequency, suggesting further clinical validation is needed for safety and efficacy.

This molecular docking study reported that danoprevir, remdesivir, and saridegib exhibit stronger binding affinities to the main protease of SARS-CoV-2 than the control, suggesting their potential as inhibitors of the virus's replication process.

This review discusses drug repurposing for various conditions, including cancer and COVID-19, highlighting ongoing trials with potential repurposed drugs but provides no new clinical results.

In this case study, a 29-year-old male with severe atopic dermatitis and alopecia universalis experienced an excellent response to treatment with upadacitinib, indicating it may be a promising option for similar patients.

Apremilast may help treat hair loss in alopecia areata.